Search

Your search keyword '"Lheureux, Stephanie"' showing total 646 results
Start Over Author "Lheureux, Stephanie"
646 results on '"Lheureux, Stephanie"'

1. Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib

Author

Barnicle, Alan, Ray-Coquard, Isabelle, Rouleau, Etienne, Cadoo, Karen, Simpkins, Fiona, Aghajanian, Carol, Leary, Alexandra, Poveda, Andrés, Lheureux, Stephanie, Pujade-Lauraine, Eric, You, Benoit, Ledermann, Jonathan, Matulonis, Ursula, Gourley, Charlie, Timms, Kirsten M., Lai, Zhongwu, Hodgson, Darren R., Elks, Cathy E., Dearden, Simon, Egile, Coumaran, Lao-Sirieix, Pierre, Harrington, Elizabeth A., and Brown, Jessica S.

Published
2024
Full Text
View/download PDF

3. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Author

Marth, Christian, Moore, Richard G., Bidziński, Mariusz, Pignata, Sandro, Ayhan, Ali, Rubio, M. Jesús, Beiner, Mario, Hall, Marcia, Vulsteke, Christof, Braicu, Elena Ioana, Sonoda, Kenzo, Wu, Xiaohua, Frentzas, Sophia, Mattar, André, Lheureux, Stephanie, Chen, Xiaojun, Hasegawa, Kosei, Magallanes-Maciel, Manuel, Choi, Chel Hun, Shalkova, Mariia, Kaen, Diego, Wang, Peng-Hui, Berger, Regina, Okpara, Chinyere E., McKenzie, Jodi, Yao, Lili, Orlowski, Robert, Khemka, Vivek, Gilbert, Lucy, Makker, Vicky, Kaen, Diego Lucas, Gomez Abuin, Gonzalo, Zamora, Liliana Beatriz, Alfie, Margarita Sonia, Casarini, Ignacio Alfredo, Harrison, Michelle, Ananda, Sumitra, Shannon, Catherine Margaret, Frentzas, Sophia, Friedlander, Michael, Meniawy, Tarek, Gao, Bo, Baron-Hay, Sally, Diakos, Connie, Marth, Christian, Polterauer, Stephan, Petru, Edgar, De Bock, Marlies, Vulsteke, Christof, Baurain, Jean-Francois, Van Gorp, Toon, Altintas, Sevilay, Lima, Joao Paulo da Silveira Nogueira, Mattar, Andre, de Freitas Junior, Ruffo, Santana, Rosane O., de Melo, Andreia Cristina, Franke, Fabio Andre, Zibetti Dal Molin, Graziela, Damian, Fernanda Bronzon, Guedes, João Daniel Cardoso, Ellard, Susan, Tinker, Anna, Samouëlian, Vanessa, Fortin, Suzanne, Bessette, Paul, Kolinsky, Michael, Kumar Tyagi, Nidhi, Ethier, Josee-Lyne, Gilbert, Lucy, Lheureux, Stephanie, MacKay, Helen, Lim, Charles, Wu, Xiaohua, Pan, Lingya, An, Ruifang, Chen, Xiaojun, Zheng, Hong, Wu, Yumei, Zhu, Jianqing, Yao, Shuzhong, Jia, Xuemei, Huang, Yi, Lv, Weiguo, Zhang, Yu, Zhou, Qi, Ma, Cailing, Chekerov, Radoslav, Mach, Pawel, Witteler, Ralf, Marmè, Frederik, Cadoo, Karen, Korach, Jacob, Levy, Talia, Beiner, Mario, Amnon, Amit, Scollo, Paolo, Naglieri, Emanuele, Pignata, Sandro, Zamagni, Claudio, Salutari, Vanda, Usami, Tomoka, Nakamura, Kazuto, Matsumoto, Koji, Yamagami, Wataru, Kobayashi, Yoichi, Takano, Masashi, Kato, Hidenori, Sonoda, Kenzo, Kikuchi, Akira, Katsumata, Noriyuki, Kamiura, Shoji, Horie, Koji, Hasegawa, Kosei, Tsunoda, Takuya, Suzuki, Nao, Yunokawa, Mayu, Nishio, Shin, Kudaka, Wataru, Guerrero Cabrera, Fernando Felix, Gonzalez Mendoza, Rene Lazaro, Magallanes Maciel, Manuel Ernesto, Villalobos Valencia, Ricardo, Escobar Penagos, Jose, Lopez Chuken, Yamil Alonso, Mackowiak-Matejczyk, Beata, Tarnawski, Rafal, Kalinka, Ewa, Bidzinski, Mariusz, Bednarek, Wieslawa, Danska-Bidzinska, Anna, Koralewski, Piotr, Roszak, Andrzej, Kedrova, Anna, Musaeva, Natalia, Urmancheeva, Adiliya Fettekhovna, Vasiliev, Aleksandr Gennadievich, Safina, Sufia Zievna, Lisyanskaya, Alla Sergeevna, Rykov, Ivan V., Rumyantsev, Alexey Alexandrovich, Belonogov, Aleksandr, Makarycheva, Yulia, Kim, Yong Man, Choi, Chel Hun, Kim, Yong Beom, Kim, Hee Seung, Kim, Sang Wun, Quindos Varela, Maria, Casado Herraez, Antonio, Diaz Redondo, Tamara, Rubio Perez, Maria Jesus, Romeo Marin, Margarita, Romero Noguera, Ignacio, Taus Garcia, Alvaro, Lin, Wu-Chou, Chou, Hung-Hsueh, Cheng, Wen-Fang, Lu, Chien-Hsing, Wang, Peng-Hui, Simsek, Tayup, Kose, Fatih, Ayhan, Ali, Vardar, Mehmet Ali, Ozerkan, Kemal, Hughes, Andrew, Stillie, Alison, Eminowicz, Gemma, Khalique, Saira, Shalkova, Mariia, Sukhina, Olena, Piatnytska, Tetiana, Averina, Hanna, Kulyaba, Yaroslav, Kryzhanivska, Anna, Bondarenko, Igor, Svintsitsky, Valentyn, Krasnohrud, Yuliia, Voitko, Nataliia, Buscema, Joseph, Ghamande, Sharad, Lewin, Sharyn, Graham, Deena M., Makker, Vicky, Bell, Maria, Santin, Alessandro, Lee, Christine, Blank, Stephanie, Konecny, Gottfried E., Corr, Bradley, Van Le, Linda, Moore, Richard G., Scalici, Jennifer, Anderson, Charles, Braly, Patricia, Fehniger, Julia, Westhoff, Gina, and Bollinger, Lauren

Published
2024
Full Text
View/download PDF

4. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Author

May, Taymaa, Bernardini, Marcus, Lheureux, Stephanie, Aben, Katja KH, Bandera, Elisa V, Beckmann, Matthias W, Benitez, Javier, Berchuck, Andrew, Bjørge, Line, Carney, Michael E, Cramer, Daniel W, deFazio, Anna, Dörk, Thilo, Eccles, Diana M, Friedlander, Michael, García, María Jose, Goode, Ellen L, Hein, Alexander, Høgdall, Claus K, Jensen, Allan, Johnatty, Sharon, Kennedy, Catherine J, Kiemeney, Lambertus A, Kjær, Susanne K, Kupryjańczyk, Jolanta, Matsuo, Keitaro, McGuire, Valerie, Modugno, Francesmary, Paddock, Lisa E, Pejovic, Tanja, Phelan, Catherine M, Riggan, Marjorie J, Rodriguez-Antona, Cristina, Rothstein, Joseph H, Sieh, Weiva, Song, Honglin, Terry, Kathryn L, van Altena, Anne M, Vanderstichele, Adriaan, Vergote, Ignace, Thomsen, Liv Cecilie Vestrheim, Webb, Penelope M, Wentzensen, Nicolas, Wilkens, Lynne R, Ziogas, Argyrios, Jiang, Haiyan, and Tone, Alicia

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Ovarian Cancer, Women's Health, Rare Diseases, Cancer, 6.4 Surgery, Humans, Female, Middle Aged, Retrospective Studies, Neoplasm Staging, Ovarian Neoplasms, Cystadenocarcinoma, Serous, Kaplan-Meier Estimate, Ovarian Cancer Association and the Australian Ovarian Cancer Study Group, Clinical Sciences, Surgery, Clinical sciences
Abstract

BackgroundWomen with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.MethodsWe performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.ResultsOf the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.ConclusionThis multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

Published
2023

5. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Author

Lee, Jung-Min, Brady, Mark F., Miller, Austin, Moore, Richard G., MacKay, Helen, McNally, Leah, Lea, Jayanthi, Street, Daron, Lheureux, Stephanie, McDonald, Megan E., Duska, Linda R., Cantuaria, Guilherme, Kavecansky, Juraj, Leath, Charles A., III, Powell, Matthew, Cadungog, Mark G., Rose, Peter G., Kim, Yong-Man, Huang, Helen Q., Provencher, Michèle, Wenzel, Lari B., Bookman, Michael A., Kohn, Elise C., and Secord, Angeles Alvarez

Published
2024
Full Text
View/download PDF

7. Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers

Author

Madariaga, Ainhoa, Jivraj, Nazlin, Soberanis Pina, Pamela, Somji, Faiza, Truong, Tran, Melwani, Sheena, Lovas, Mike, Gogos, Terri-Ann, Sajewycz, Katrina, Bhat, Gita, Alqaisi, Husam, Gonzalez-Ochoa, Eduardo, Veneziani, Ana, Garg, Vikas, Dhani, Neesha C, Grant, Robert, Bowering, Valerie, Oza, Amit M, Wang, Lisa, Berlin, Alejandro, Lheureux, Stephanie, and Foote, Janie

Published
2024
Full Text
View/download PDF

8. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Barretina-Ginesta, Pilar, Bennett, Katherine, Berek, Jonathan, Berger, Regina, Bjørge, Line, Boere, Ingrid, Brennan, Donal, Bruchim, Ilan, Chang, Ting-Chang, Chavez Blanco, Adriana, Chen, Xiaojun, Colombo, Nicoletta, Crosbie, Emma, Denys, Hannelore, Duska, Linda, Fruehauf, Filip, Gomez Garcia, Eva Maria, van Gorp, Toon, Grimm, Christoph, Guitmann, Gustavo, Han, Kathy, Hanker, Lars, Harano, Kenichi, Hasegawa, Kosei, Herrington, C Simon, Ip, Philip, Joly, Florence, Khaw, Pearly, Kohn, Elise, Kristeleit, Rebecca, Kroep, Judith, Leary, Alexandra, Lee, Jung-Yun, Lheureux, Stephanie, Liu, Jihong, Mackay, Helen, Mahner, Sven, Mariani, Andrea, McAlpine, Jessica, Mikami, Yoshiki, Mirza, Mansoor Raza, Mukhopadhyay, Asima, Nagao, Shoji, Ng, Joseph, Nogueira-Rodrigues, Angelica, Novák, Zoltán, O'Donnell, Jennifer, Osborne, Sherill, Perez-Fidalgo, J. Alejandro, Romeo Marin, Margarita, Roy Chowdhury, Rahul, Sadozye, Azmat, Safra, Tamar, Scott, Claire, Sehouli, Jalid, Slomovitz, Brian, Tan, David, Taylor, Alexandra, Valabrega, Giorgio, Veneziani, Ana, Verhoeven, Karen, Vetter, Marcus, Wampfler, Julian, Westin, Shannon, Wimberger, Pauline, Zola, Paolo, Creutzberg, Carien L, Kim, Jae-Weon, Eminowicz, Gemma, Allanson, Emma, Eberst, Lauriane, Kim, Se Ik, Nout, Remi A, Park, Jeong-Yeol, Lorusso, Domenica, Mileshkin, Linda, Ottevanger, Petronella B, Brand, Alison, Mezzanzanica, Delia, Oza, Amit, Gebski, Val, Pothuri, Bhavana, Batley, Tania, Gordon, Carol, Mitra, Tina, White, Helen, Howitt, Brooke, Matias-Guiu, Xavier, Ray-Coquard, Isabelle, Gaffney, David, Small, William, Jr, Miller, Austin, Concin, Nicole, Powell, Matthew A, Stuart, Gavin, and Bookman, Michael A

Published
2024
Full Text
View/download PDF

11. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Author

Hernando-Calvo, Alberto, Yang, S.Y. Cindy, Vila-Casadesús, Maria, Han, Ming, Liu, Zhihui Amy, Berman, A Hal K., Spreafico, Anna, Razak, Albiruni Abdul, Lheureux, Stephanie, Hansen, Aaron R., Lo Giacco, Deborah, Abbas-Aghababazadeh, Farnoosh, Matito, Judith, Haibe-Kains, Benjamin, Pugh, Trevor J., Bratman, Scott V., Aleshin, Alexey, Berche, Roger, Saavedra, Omar, Garralda, Elena, Elston, Sawako, Siu, Lillian L., Ohashi, Pamela S., Vivancos, Ana, and Bedard, Philippe L.

Published
2024
Full Text
View/download PDF

12. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Author

Yap, Timothy A., Fontana, Elisa, Lee, Elizabeth K., Spigel, David R., Højgaard, Martin, Lheureux, Stephanie, Mettu, Niharika B., Carneiro, Benedito A., Carter, Louise, Plummer, Ruth, Cote, Gregory M., Meric-Bernstam, Funda, O’Connell, Joseph, Schonhoft, Joseph D., Wainszelbaum, Marisa, Fretland, Adrian J., Manley, Peter, Xu, Yi, Ulanet, Danielle, Rimkunas, Victoria, Zinda, Mike, Koehler, Maria, Silverman, Ian M., Reis-Filho, Jorge S., and Rosen, Ezra

Published
2023
Full Text
View/download PDF

14. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Author

Madariaga, Ainhoa, Garg, Swati, Tchrakian, Nairi, Dhani, Neesha C., Jimenez, Waldo, Welch, Stephen, MacKay, Helen, Ethier, Josee-Lyne, Gilbert, Lucy, Li, Xuan, Rodriguez, Angela, Chan, Lucy, Bowering, Valerie, Clarke, Blaise, Zhang, Tong, King, Ian, Downs, Gregory, Stockley, Tracy, Wang, Lisa, Udagani, Smitha, Oza, Amit M., and Lheureux, Stephanie

Published
2023
Full Text
View/download PDF

16. Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy

Author

Aguilar-Mahecha, Adriana, Aronson, Melyssa, Basik, Mark, Baxter, Nancy N., Bedard, Phil, Berman, Hal, Bernardini, Marcus Q., Bombard, Yvonne, Carile, Victoria, Chan, Clarissa F., Cil, Tulin, Clarke, Blaise, Dawson, Lesa, Dhalla, Irfan, Elser, Christine, Ene, Gabrielle EV., Farncombe, Kirsten M., Ferguson, Sarah, Foulkes, William D., Genge, Laura, Gryfe, Robert, Jacobson, Michelle R., Karsan, Aly, Kastner, Monika, Kaurah, Pardeep, Kim, Raymond H., Lafleur, Josiane, Lerner-Ellis, Jordan, Lheureux, Stephanie, MacDonald, Shelley M., McCuaig, Jeanna, Mckee, Brian, Mittmann, Nicole, Norman, Maia L., Oldfield, Leslie E., Panchal, Seema, Penney, Lynette S., Piccinin, Carolyn, Pollett, Aaron, Pugh, Trevor J., Regier, Dean, Rezoug, Zoulikha, Rideout, Krista, Schrader, Kasmintan A., Semotiuk, Kara, Singh, Sara, Siu, Lillian, Sobotka, Julia A., Sun, Sophie, Thain, Emily, Wallace, Karin, Ward, Thomas, Westergard, Shelley, Whittle, Stacy, Xu, Wei, Yu, Celeste, Wong, Derek, Malkin, David, and Parkin, Patricia

Published
2023
Full Text
View/download PDF

21. Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study

Author

Zimmermann, Camilla, Pope, Ashley, Hannon, Breffni, Bedard, Philippe L., Rodin, Gary, Dhani, Neesha, Li, Madeline, Herx, Leonie, Krzyzanowska, Monika K., Howell, Doris, Knox, Jennifer J., Leighl, Natasha B., Sridhar, Srikala, Oza, Amit M., Lheureux, Stephanie, Booth, Christopher M., Liu, Geoffrey, Castro, Jacqueline Alcalde, Swami, Nadia, Sue-A-Quan, Rachel, Rydall, Anne, and Le, Lisa W.

Published
2023
Full Text
View/download PDF

23. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma

Author

Madariaga, Ainhoa, Mitchell, Sandra A., Pittman, Tyler, Wang, Lisa, Bowering, Valerie, Kavak, Nisan, Quintos, Judy, Chang, Karen, Ramsahai, Janelle, Karakasis, Katherine, Welch, Stephen A., Dhani, Neesha C., Lheureux, Stephanie, and Oza, Amit M.

Published
2022
Full Text
View/download PDF

26. Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-OV80).

Author

Jung-Yun Lee, Tan, David, Ray-Coquard, Isabelle, Jung Bok Lee, Byoung Gie Kim, Van Nieuwenhuysen, Els, Yun-Ju Huang, Ruby, Ka Yu Tse, González-Martin, Antonio, Scott, Clare, Hasegawa, Kosei, Wilkinson, Katie, Eun Yeong Yang, Lheureux, Stephanie, and Kristeleit, Rebecca

Abstract

Background: Recurrent gynecological clear cell carcinoma (rGCCC) has a low objective response rate (ORR) to chemotherapy. Previous preclinical and clinical data suggest a potential synergy between immune checkpoint inhibitors and bevacizumab in rGCCC. Dostarlimab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), combined with the anti-angiogenic bevacizumab, presents a novel therapeutic approach. This study will investigate the efficacy of dostarlimab +/- bevacizumab in rGCCC. Methods: DOVE is a global, multicenter, international, open-label, randomized phase 2 study of dostarlimab +/- bevacizumab with standard chemotherapy in rGCCC. We will enroll 198 patients with rGCCC and assign them to one of three groups in a 1:1:1 ratio: arm A (dostarlimab monotherapy), B (dostarlimab + bevacizumab), and C (investigator's choice of chemotherapy [weekly paclitaxel, pegylated liposomal doxorubicin, doxorubicin, or gemcitabine]). Patients with disease progression in arm A or C will be allowed to cross over to arm B. Stratification factors include prior bevacizumab use, prior lines of therapy (1 vs. >1), and primary site (ovarian vs. non-ovarian). Key inclusion criteria are histologically proven recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, or vulva; up to five prior lines of therapy; disease progression within 12 months after platinum-based chemotherapy; and measurable disease. Key exclusion criteria are prior treatment with an anti-PD-1, anti-programmed death-ligand 1, or anti-programmed death-ligand 2 agent. The primary endpoint is progression-free survival determined by investigators. Secondary endpoints are ORR, disease control rate, clinical benefit rate, progression-free survival 2, overall survival, and toxicity. Exploratory objectives include immune biomarkers. Trial Registration: ClinicalTrials.gov Identifier: NCT06023862 [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

27. Novel Systemic Anticancer Therapy and Healthcare Utilization at the End of Life: A Retrospective Cohort Study.

Author

Garg, Vikas, Ruiz Buenrostro, Alejandra, Heuniken, Katrina, Bagnarol, Rebecca, Yousef, Mohamed, Sajewicz, Katrina, Dhanju, Suman, Wentlandt, Kirsten, Kuruvilla, John, Lheureux, Stephanie, Zimmermann, Camilla, and Hannon, Breffni

Subjects
ADVANCE directives (Medical care), MEDICAL care use, EMERGENCY room visits, INTENSIVE care units, HEMATOLOGIC malignancies
Abstract

Background: Novel systemic anticancer therapies (SACT) in the form of targeted and immunotherapies are increasingly replacing traditional chemotherapy. Little is known about the impact of novel SACT on healthcare resource utilization (HCRU) at the end of life. Methodology: A retrospective review of patients attending a tertiary cancer center in Toronto, Canada, with advanced solid or hematological malignancies who died in 2019. Demographic and cancer data, SACT use, HCRU (emergency room [ER] visits, acute/intensive care unit [ICU] admission, and place of death) were retrieved and compared between those who received SACT in their last 30 days of life and those who did not. Chi‐squared tests or Quasi‐Poisson regression calculated HCRU expressed as percentages or rate ratios (RR). Univariate and multivariable logistic regression identified factors independently associated with SACT use. Results: Of 443 patients included, 88 (20%) received SACT in the last 30 days of life, with 42 (48%) receiving targeted therapies and 10 (11%) immunotherapy. Factors associated with SACT use included younger age (p = 0.016), breast (p < 0.001), lung (p = 0.047), hematological malignancies (p = 0.002), fewer comorbidities (p = 0.039), and novel SACT (p = 0.006). Receipt of SACT was associated with a higher frequency of ER visits (55% vs. 36% who did not receive SACT, p = 0.001), acute hospitalizations (68% vs. 47%, p < 0.001), ICU admissions (18% vs. 7%, p = 0.003), and death in hospital (45% vs. 30%, p = 0.008). Conclusion: Novel SACT use at the end of life is high and is strongly associated with HCRU. Future studies should explore the impact of advance care planning and palliative care referrals on SACT use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching.

Author

Grant, Brooke, primary, Pannu, Anmol Kaur, additional, Bowering, Valerie, additional, Veneziani, Ana, additional, Soberanis Pina, Pamela, additional, Gonzalez-Ochoa, Eduardo, additional, Alqaisi, Husam, additional, Garg, Vikas, additional, Braik, Dina, additional, Hodgson, Anjelica, additional, Rouzbahman, Marjan, additional, Chawla, Tanya, additional, Msan, Anthony, additional, Siman, Steven, additional, King, Ian, additional, Stockley, Tracy, additional, Grant, Robert C, additional, Dhani, Neesha C., additional, Lheureux, Stephanie, additional, and Oza, Amit M., additional

Published
2024
Full Text
View/download PDF

31. Molecular characterization of cervical cancer histological subtypes: The VENUS study.

Author

Braik, Dina, primary, Alqaisi, Husam, additional, Garg, Vikas, additional, Soberanis Pina, Pamela, additional, Valente Lage, Liana, additional, Veneziani, Ana, additional, Grant, Brooke, additional, Pannu, Anmol Kaur, additional, Lajkosz, Katherine, additional, Msan, Anthony, additional, Hodgson, Anjelica, additional, Rouzbahman, Marjan, additional, Stockley, Tracy, additional, Bowering, Valerie, additional, Grant, Robert C, additional, Dhani, Neesha C., additional, Lheureux, Stephanie, additional, and Oza, Amit M., additional

Published
2024
Full Text
View/download PDF

32. Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.

Author

Lheureux, Stephanie, primary, May, Taymaa, additional, Wilson, Michelle K., additional, Provencher, Diane M., additional, Lau, Susie, additional, Ghatage, Prafull, additional, Weberpals, Johanne I, additional, Banerjee, Susana N., additional, McNeish, Iain A., additional, Dhani, Neesha C., additional, Ferguson, Sarah, additional, Bouchard-Fortier, Genevieve, additional, Pugh, Trevor John, additional, Ye, Xiang Y, additional, Garisto, Sarah, additional, Quintos, Judy, additional, Ramsahai, Janelle, additional, Wong, Horace, additional, Bowering, Valerie, additional, and Oza, Amit M., additional

Published
2024
Full Text
View/download PDF

37. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Author

Lheureux, Stephanie, Cristea, Mihaela C, Bruce, Jeffrey P, Garg, Swati, Cabanero, Michael, Mantia-Smaldone, Gina, Olawaiye, Alexander B, Ellard, Susan L, Weberpals, Johanne I, Wahner Hendrickson, Andrea E, Fleming, Gini F, Welch, Stephen, Dhani, Neesha C, Stockley, Tracy, Rath, Prisni, Karakasis, Katherine, Jones, Gemma N, Jenkins, Suzanne, Rodriguez-Canales, Jaime, Tracy, Michael, Tan, Qian, Bowering, Valerie, Udagani, Smitha, Wang, Lisa, Kunos, Charles A, Chen, Eric, Pugh, Trevor J, and Oza, Amit M

Published
2021
Full Text
View/download PDF

40. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).

Author

Fontana, Elisa, Rosen, Ezra, Lee, Elizabeth K, Højgaard, Martin, Mettu, Niharika B, Lheureux, Stephanie, Carneiro, Benedito A, Cote, Gregory M, Carter, Louise, Plummer, Ruth, Mahalingam, Devalingam, Fretland, Adrian J, Schonhoft, Joseph D, Silverman, Ian M, Wainszelbaum, Marisa, Xu, Yi, Ulanet, Danielle, Koehler, Maria, and Yap, Timothy A

Subjects
CIRCULATING tumor DNA, DNA repair, ATAXIA telangiectasia, BIOMARKERS, ADVERSE health care events
Abstract

Background Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. On-target anemia is the main drug-related toxicity typically manifesting after the period of dose-limiting toxicity evaluation. Thus, dose and schedule optimization requires extended follow-up to assess prolonged treatment effects. Methods Long-term safety, tolerability, and antitumor efficacy of 3 camonsertib monotherapy dosing regimens were assessed in the TRESR study dose-optimization phase: 160 mg once daily (QD) 3 days on, 4 days off (160 3/4; the preliminary recommended Phase II dose [RP2D]) and two step-down groups of 120 mg QD 3/4 (120 3/4) and 160 mg QD 3/4, 2 weeks on, 1 week off (160 3/4, 2/1w). Safety endpoints included incidence of treatment-related adverse events (TRAEs), dose modifications, and transfusions. Efficacy endpoints included overall response rate, clinical benefit rate, progression-free survival, and circulating tumor DNA (ctDNA)-based molecular response rate. Results The analysis included 119 patients: 160 3/4 (n = 67), 120 3/4 (n = 25), and 160 3/4, 2/1w (n = 27) treated up to 117.1 weeks as of the data cutoff. The risk of developing grade 3 anemia was significantly lower in the 160 3/4, 2/1w group compared with the preliminary RP2D group (hazard ratio = 0.23, 2-sided P  = .02), translating to reduced transfusion and dose reduction requirements. The intermittent weekly schedule did not compromise antitumor activity. Conclusion The 160 3/4, 2/1w dose was established as an optimized regimen for future camonsertib monotherapy studies offering a substantial reduction in the incidence of anemia without any compromise to efficacy. Clinical Trial ID NCT04497116. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences

Author

Madariaga, Ainhoa, primary, Bhat, Gita, additional, Wilson, Michelle K., additional, Li, Xuan, additional, Cyriac, Sunu, additional, Bowering, Valerie, additional, Hunt, Wendy, additional, Gutierrez, David, additional, Bonilla, Luisa, additional, Kasherman, Lawrence, additional, McMullen, Michelle, additional, Wang, Lisa, additional, Ghai, Sangeet, additional, Dhani, Neesha C., additional, Oza, Amit M., additional, and Lheureux, Stephanie, additional

Published
2024
Full Text
View/download PDF

46. Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Author

Stutheit-Zhao, Eric Y., primary, Sanz-Garcia, Enrique, additional, Liu, Zhihui (Amy), additional, Wong, Derek, additional, Marsh, Kayla, additional, Abdul Razak, Albiruni R., additional, Spreafico, Anna, additional, Bedard, Philippe L., additional, Hansen, Aaron R., additional, Lheureux, Stephanie, additional, Torti, Dax, additional, Lam, Bernard, additional, Yang, Shih Yu Cindy, additional, Burgener, Justin, additional, Luo, Ping, additional, Zeng, Yong, additional, Cheng, Nicholas, additional, Awadalla, Philip, additional, Bratman, Scott V., additional, Ohashi, Pamela S., additional, Pugh, Trevor J., additional, and Siu, Lillian L., additional

Published
2024
Full Text
View/download PDF

47. Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial

Author

Veneziani, Ana C., primary, Alqaisi, Husam, additional, Millar, Douglas G, additional, Colombo, Ilaria, additional, Gonzalez-Ochoa, Eduardo, additional, Atale, Swati, additional, Msan, Anthony, additional, Quintos, Judy, additional, Ramsahai, Janelle, additional, Garg, Vikas, additional, Soberanis, Pamela, additional, Dhani, Neesha C, additional, Grant, Robert C, additional, Wang, Lisa, additional, Bowering, Valerie, additional, Lheureux, Stephanie, additional, Ohashi, Pamela S, additional, and Oza, Amit M, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results